Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals Inc. (CTXR) delivers innovative therapies for critical care needs through its pipeline of novel oncology treatments and anti-infective solutions. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's progress.
Access verified information about CTXR's FDA interactions, trial results for therapies like LYMPHIR™ and Mino-Lok®, and partnership announcements. Our curated collection ensures you stay informed about material events without promotional bias, supporting data-driven decision-making in this specialized biopharmaceutical sector.
Key updates include progress reports on late-stage clinical programs, manufacturing expansions, and peer-reviewed research publications. All content undergoes strict verification to maintain compliance with financial disclosure standards while preserving accessibility for both medical and investment audiences.
Bookmark this page for streamlined tracking of CTXR's advancements in targeted immunotherapies and critical care innovations. Combine regular monitoring with professional financial advice to maintain perspective on the company's evolving market position.
Novellus Therapeutics has licensed its induced mesenchymal stem cells (iMSCs) to NoveCite, a new subsidiary of Citius Pharmaceuticals (Nasdaq: CTXR). The agreement includes a $5 million upfront payment and potential milestone payments totaling up to $51 million, alongside low double-digit royalties. NoveCite aims to utilize these iMSCs to address acute respiratory conditions, particularly Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. Novellus holds a 25% equity stake in NoveCite, indicating a significant collaborative effort to innovate treatment options in critical care.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced on October 7, 2020, an exclusive licensing agreement with Novellus Therapeutics for iPSC-derived mesenchymal stem cells (NC-iMSCs), targeting acute respiratory conditions like Acute Respiratory Distress Syndrome (ARDS) related to COVID-19. This collaboration forms a new subsidiary, NoveCite, which aims to develop NC-iMSCs, believed to have superior potency and unlimited supply compared to traditional donor-derived stem cells. With over 3 million ARDS cases annually, this therapy holds potential for significant impact in critical care.
Citius Pharmaceuticals (CTXR) announced on September 30, 2020, that the Mino-Lok Clinical Trial Material at clinical sites has been replaced with registration batch product. This transition allows trial participants to receive Mino-Lok manufactured with the same process intended for commercial use post-FDA approval. CEO Myron Holubiak expressed satisfaction in providing common packaging for Mino-Lok components and indicated readiness for commercial manufacturing following successful Phase 3 trials and FDA clearance.
Citius Pharmaceuticals (Nasdaq: CTXR) announced positive outcomes from a Data Monitoring Committee (DMC) meeting regarding its Mino-Lok phase 3 trial. The DMC found no safety signals and recommended continuing the trial without modifications. Despite challenges in patient recruitment during the COVID-19 pandemic, the company is nearing the late stage of the pivotal study. CEO Myron Holubiak expressed confidence in Mino-Lok's safety and efficacy, highlighting the dedication of study investigators amidst challenges.
Citius Pharmaceuticals, Inc. (CTXR) has announced significant milestones for its antibiotic lock solution, Mino-Lok, designed for treating central line-associated bloodstream infections. The company has manufactured three registration lots for the New Drug Application (NDA) and placed them on stability at ICH conditions. Additionally, an exclusive synthesis process for EDTA has been developed. CEO Myron Holubiak emphasized the uniqueness of Mino-Lok, which includes three active drug substances. Citius aims to commence commercial manufacturing following the completion of a Phase 3 clinical trial and FDA approval.
Citius Pharmaceuticals (Nasdaq: CTXR) has filed an amendment to the Mino-Lok phase 3 protocol to improve clinical trial record-keeping amid COVID-19. This adjustment aims to address challenges faced in the ICU due to restricted personal visits. The company remains committed to collaborating with Principle Investigators for effective trial management. CEO Myron Holubiak expressed optimism about ongoing trials despite significant hurdles and anticipates a Drug Monitoring Committee meeting at the end of the month.
Citius Pharmaceuticals (Nasdaq: CTXR) announced its presentation at the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 14-16, 2020. Chairman Leonard Mazur will present on September 15 at 11:00 a.m. ET, discussing the company’s recent expansion in intellectual property related to Mino-Wrap and plans to address acute respiratory distress syndrome (ARDS) related to COVID-19. Additionally, updates on Mino-Lok® will be provided, focusing on catheter-related bloodstream infections. Virtual one-on-one investor meetings will also be conducted.
Citius Pharmaceuticals (Nasdaq: CTXR) will present at the 12th annual LD Micro LD 500 conference on September 1 at 11:00 AM ET. Chairman Leonard Mazur will provide updates on the company's product developments, including treatments for acute respiratory distress syndrome related to COVID-19. This virtual event, accessible to all, runs from September 1 to September 4. This marks a significant opportunity for investors to gain insights into Citius’s strategic direction and product pipeline.
Citius Pharmaceuticals (CTXR) has expanded its intellectual property related to Mino-Wrap, a novel product aimed at reducing post-mastectomy infections involving tissue expanders. The USPTO has granted patent 10,434,221 B2, enhancing the design and application of Mino-Wrap under a global license agreement with MD Anderson Cancer Center. Approximately 100,000 U.S. patients undergo breast reconstruction annually, with infection rates for tissue expanders ranging from 2.5% to 24%. Mino-Wrap aims to significantly decrease this infection risk, potentially improving patient outcomes and reducing hospitalization.
Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in the MoneyShow Las Vegas Virtual Expo from August 18 to 20, 2020. The company's presentation is scheduled for August 19 at 4:50 PM ET, led by Chairman Leonard Mazur. Key topics include the recent $9.6 million public stock offering and a briefing to the FDA regarding Mino-Wrap, aimed at reducing post-operative infections. Investors can register for the event to access the live webcast.
FAQ
What is the current stock price of Citius Pharmaceuticals (CTXR)?
What is the market cap of Citius Pharmaceuticals (CTXR)?
